Success Story: Designing Safer Drug Candidates Through Medicinal Chemistry: NIW Approved for a Sri Lankan Scientist Advancing Therapeutic Targeting and Biomarker-Informed Testing
Client’s Testimonial:
"I had an excellent experience working with Chen Immigration Lawyers on my I-140 petition. Their team is extremely detail-oriented and well-organized, which gave me confidence throughout the entire process. They were always responsive, typically replying within 1–2 days, and ensured that all documents were prepared and submitted within the required timelines. Overall, they were very professional, efficient, and easy to work with. I highly recommend their services.”
On April 22nd, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Scientist in the field of Medicinal Chemistry (Approval Notice).
General Field: Medicinal Chemistry
Position at the Time of Case Filing: Scientist
Country of Origin: Sri Lanka
State of Residence at the Time of Filing: Colorado
Approval Notice Date: April 22nd, 2026
Processing Time: 1 year, 1 month, 19 days
Case Summary:
Cancer, chronic pain, and difficult infections share a frustrating pattern. Promising drug concepts can fall short when side effects are too severe or when resistance limits durable benefit. This NIW approval highlights a Sri Lankan medicinal chemistry researcher whose proposed endeavor focuses on combining organic synthesis, advanced computational chemistry, and biological assessment to design drug candidates that remain effective while reducing unintended toxicity. At the time of filing, the client was continuing this work in the United States in an industry-aligned scientist role focused on therapeutic agent design and evaluation.
Research with National Importance
The NIW filing framed the endeavor as nationally important because safer and more targeted therapeutics can improve outcomes while reducing downstream burden on the healthcare system. The petition emphasized that scalable, evidence-grounded design and testing methods are especially valuable in areas where treatment failure and resistance remain common, including oncology, chronic pain, and infectious disease.
Academic Contributions and Recognition
To show the client was well-positioned, the petition documented 5 peer-reviewed journal articles, 9 conference abstracts, 1 preprint, 1 patent application, and 1 provisional patent application. The record also included 29 citations, reflecting early independent reliance on the client’s findings. The filing further highlighted that at least one publication achieved strong citation performance for its field and publication year, supporting influence beyond raw totals.
Recognition from Experts
The petition included expert letters explaining why medicinal chemistry advances that reduce toxicity and improve targeting are directly relevant to U.S. treatment needs, particularly for chronic pain and other high-burden conditions.
One expert stated:
“As [client]'s research fosters medical discoveries in the area of chronic pain treatment, her work is of utmost importance to the United States.”
This assessment reinforced the petition’s showing that the client’s work is recognized as practically significant and aligned with nationally important medical needs.
NIW Approval and Outlook
The I-140 NIW petition was filed on March 3rd, 2025, and approved on April 22nd, 2026. The approval reflects a cohesive NIW showing that the proposed endeavor carries substantial merit and national importance and that the client is well-positioned through a documented publication and patent record, independent citation reliance, and continued work aligned with developing safer therapeutic options for high-burden diseases.